Director James Collins resigns; Rachel King appointed to board of Fulcrum Therapeutics

Fulcrum Therapeutics, Inc.

James J. Collins resigned as Class II director effective Nov 12, 2024, not due to any disagreement with the company or board.
Board appointed Rachel King as Class II director to fill the vacancy; term expires at 2027 annual meeting.
King is independent and will serve on Compensation & Human Capital Management Committee.
King receives standard non-employee director compensation including option for 60,000 shares at $3.64 per share.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rachel King

director

FULC · Fulcrum Therapeutics, Inc.

Effective: 2024-11-12
Filed: November 12, 2024, 6:59 PM ET

On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.

Departed

James J. Collins

director

FULC · Fulcrum Therapeutics, Inc.

Effective: 2024-11-12
Successor: Rachel King
Filed: November 12, 2024, 6:59 PM ET

On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rachel King was appointed as director at Fulcrum Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James J. Collins resigned as director at Fulcrum Therapeutics, Inc..

Action: resigned
Role: director

Exact text from the filing

On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-256101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.